Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus

Blood

Volumn 97, Issue 4, 2001, Pages 844-849

  Male, C ^a   Mitchell, L ^a   Julian, J ^a   Vegh, P ^a   Joshua, P ^a   Adams, M ^a   David, M ^a   Andrew, M E ^a  

^a NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S;

ADOLESCENT; ADULT; ARTICLE; CHILD; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; THROMBOSIS;

EID: 0035865514     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.4.844     Document Type: Article

References (49)

1. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: Prevalence and clinical significance
2. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematodes: A cross-sectional study
3. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" autoantibodies
4. Antiphospholipid-protein antibodies: Laboratory detection and clinical relevance
5. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus A meta-analysis
6. The regulation of hemostasis: The protein C system
7. Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant
8. Studies of natural anticoagulant proteins and anticardiolipin antibodies in patients with the lupus anticoagulant
9. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies
10. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells
11. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism?
12. Resistance to activated protein C
13. Acquired activated protein C-resistance in patients with lupus anticoagulants
14. Studies on phospholipid antibodies, APC-resistance and associated mutation in the coagulation factor V gene
15. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphosphotipid antibodies
16. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant
17. Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome
18. Activated protein C resistance phenotype in patients with antiphospholipid antibodies
19. Risk factors for thrombosis in lupus patients
20. Natural anticoagulants in systemic lupus erythematosus: Deficiency of protein S bound to C4bp associates with recent history of venous thromboses, antiphospholipid antibodies, and the antiphospholipid syndrome
21. The thrombotic diathesis associated with the presence of phospholipid antibodies may be due to low levels of free protein S
22. Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus
23. Free protein S deficiency may be found in patients with antiphospholipid antibodies who do not have systemic lupus erythematosus
24. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies - A crucial role for acquired free protein S deficiency
25. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein s
26. Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus
27. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: A cross-sectional study
28. The 1982 revised criteria for the classification of systemic lupus erythematosus
29. Derivation of the SLEDAl: A disease activity index for lupus patients: The Committee on Prognosis Studies in SLE
30. Criteria for the diagnosis of lupus anticoagulants: An update: On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH
31. Influence of lupus anticoagulant on a commercially available kit for APC-resistance
32. Mutation in blood coagulation factor V associated with resistance to activated protein C
33. Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery
34. Sensitivity to activated protein C: Influence of oral contraceptives and sex
35. New molecular insights into the genetics of thrombophilia: Resistance to activated protein C caused by Arg506 to GIn mutation in factor V as a pathogenic risk factor for venous thrombosis
36. Development of resistance to activated protein C during pregnancy
37. A fatal thrombotic disorder associated with an acquired inhibitor of protein C
38. Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C
39. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
40. Activated protein C resistance in ischemic stroke not due to factor V arginine506→glutamine mutation
41. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease
42. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism
43. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: Relation to the pathogenesis of thrombosis
44. Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro
45. Factor V Leiden increases the risk of thrombosis in patients with antiphospholipid antibodies
46. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls
47. Modified test for activated protein C resistance
48. Modified APC resistance assay for patients on oral anticoagulants
49. Diagnosis of APC resistance in patients on oral anticoagulant therapy